Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Pazopanib (GW786034) in Patients With Advanced and Progressive Malignant Pheochromocytoma or Paraganglioma

NCT01340794 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01340794
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01340794 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Pazopanib (GW786034) in Patients With Advanced and Progressive Malignant Pheochromocytoma or Paraganglioma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Terminated
Start date
May 31, 2011
Completion date
November 30, 2014
Enrollment
7 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

extra-adrenal paraganglioma, metastatic adrenal gland pheochromocytoma, paraganglioma, recurrent adrenal gland pheochromocytoma